Merck lowered its full-year profit guidance and said tariffs would mean an extra $200 million in costs this year. The stock rose 0.6% to $79.24 shortly after it posted first quarter earnings. Shares had been up about 1% prior to the report.

Merck said the expected tariff charge primarily reflects levies between the U.S. and China, but does not account for Trump’s planned pharmaceutical tariffs.

Merck & Co. said it expects to lose $200 million to already-announced tariffs in 2025 amid a roiling trade war between the US and China.